LRA Pleased to Share GSK’s Benlysta® (belimumab) is First Lupus Nephritis Treatment Approved by FDA

NEW YORK, NY. December 17, 2020. The Lupus Research Alliance (LRA) congratulates GSK on the U.S. Food and Drug Administration (FDA) approval of belimumab (Benlysta®) as the first-ever treatment specifically indicated for lupus nephritis (LN) in adults. Another milestone, this new indication is the only FDA approval of a new lupus treatment since belimumab was first approved …

Read More

LRA Applauds GSK on Positive Phase 3 Study of Benlysta® in Lupus Nephritis

September 16, 2020 NEW YORK, NY. The Lupus Research Alliance welcomes positive BLISS-LN Phase 3 data published in this week’s New England Journal of Medicine, demonstrating that GSK’s drug Benlysta® (belimumab) significantly improved kidney function in adults with lupus nephritis, the most common severe complication of lupus causing inflammation and serious damage to the kidney. The two-year …

Read More

Sign up for our Newsletter

Use this tool to search all lupus trials and create a personalized list of studies by the type of lupus you have and where you live.

Sign up